- A patent infringement complaint reported by The National Law Review on June 9, 2026, accuses a defendant of systematically "pirating" AI-driven medical technology — language that signals an aggressive willful-infringement litigation strategy aimed at treble damages.
- Under 35 U.S.C. § 271, any entity that uses a patented AI method without authorization — including hospitals licensing third-party diagnostic tools — can face direct liability regardless of knowledge.
- The Alice Corp. v. CLS Bank (2014) Supreme Court precedent governs whether AI software patents are valid at all, making claim construction a battlefield that must be won before infringement is ever reached.
- Legal technology and law firm automation tools are now central to both building and defending AI patent cases — shortening timelines and raising stakes for every party in the healthcare supply chain.
What Happened
A single court filing can scramble years of R&D investment overnight. A patent infringement lawsuit highlighted by The National Law Review on June 9, 2026, and surfaced through Google News, alleges that a developer of AI-powered medical technology had its innovations taken without authorization — with the plaintiff's team characterizing the conduct as outright "piracy." The complaint targets the alleged unauthorized use of patented methods for applying machine-learning algorithms to medical processes: systems designed for tasks such as diagnostic imaging interpretation, patient risk scoring, or clinical decision support platforms embedded in hospital workflows.
Patent infringement in the AI context is governed by 35 U.S.C. § 271, the core federal statute prohibiting any party from making, using, selling, or importing a patented invention without the rights-holder's permission. For AI systems, the legal analysis turns not on whether the defendant used broadly "similar" technology, but on whether their specific product practices the exact technical "claims" written into the plaintiff's patent document — the precise step-by-step methods and system architectures that define the scope of protection. The "piracy" framing is not accidental: it positions the alleged copying as deliberate and willful, which opens the door to treble damages (a court-ordered tripling of the monetary award) if the plaintiff prevails at trial.
As of June 9, 2026, the total damages sought in this matter have not been publicly disclosed in the reporting reviewed. However, the willfulness framing — consistently emphasized in The National Law Review's coverage — indicates the plaintiff is positioning for the maximum remedy available under federal patent law, not a licensing settlement.
Photo by Defne Kucukmustafa on Unsplash
Why It Matters for You
Building on the legal stakes outlined in the complaint, the implications here extend far beyond the two named parties — and that is precisely what makes this case worth understanding whether you work in healthcare, technology procurement, or neither.
Consider the scale of what is being contested. As of June 9, 2026, the global artificial intelligence in healthcare market is valued at approximately $45 billion, according to multiple industry research and market intelligence compilations, with continued expansion driven by diagnostic AI, predictive analytics, and robotic surgery assistance tools. When a lawsuit in this sector invokes "piracy," it signals that companies competing for this market are treating patent portfolios as offensive weapons — not defensive filing exercises.
Chart: Estimated AI-related medical patent infringement filings in U.S. federal courts, 2021–2025. Figures represent industry legal analytics estimates illustrating trend direction; current as of June 9, 2026.
The statute at the center of cases like this — 35 U.S.C. § 271 — does not exempt a hospital, health system, or research institution that licenses an infringing product in good faith. Under the direct infringement doctrine, any entity that "uses" a patented invention without authorization can face liability, regardless of whether it knew the upstream technology was legally disputed. This is where the supply chain of AI medical tools carries real exposure: a radiology group running an algorithm-powered imaging platform, a pharmaceutical company integrating third-party predictive analytics into clinical trials, or a health insurer deploying AI-driven claims review software — all sit downstream from technology that could be contested in a lawsuit exactly like the one reported on June 9, 2026.
The precedent governing whether AI patents are even valid in the first place is Alice Corp. v. CLS Bank International (2014), which remains the Supreme Court's controlling framework for software patent eligibility. Under the two-step Alice test, a court first asks whether the patent claims are directed at an abstract idea — a question that routinely invalidates AI patents that describe general concepts rather than specific technical implementations. If the answer is yes, the court then asks whether the claims add something "significantly more" than that abstract idea. Surviving Alice scrutiny requires describing a precise, novel technical architecture — the specific training methodology, data preprocessing pipeline, or inference mechanism — not simply the notion of "using machine learning for diagnosis." For plaintiffs in medical AI patent litigation, building an Alice-resistant patent is prerequisite work. Without it, the case can collapse before infringement is ever adjudicated.
This escalating pattern of IP conflict over AI systems connects directly to what Smart AI Trends identified in its recent analysis of AI governance guardrails: the window to establish clear legal and technical boundaries around AI systems is narrowing, and courts are increasingly asked to fill the gaps that industry self-regulation has left open.
The AI Angle
There is a pronounced irony threading through this lawsuit: the same legal technology reshaping how law firms practice is now being deployed to litigate over AI itself. Law firm automation tools built on large language models can parse thousands of patent documents overnight, surfacing claim overlaps that human reviewers would spend weeks identifying across technically dense patent specifications. AI legal tools from patent analytics vendors can score infringement probability on a claim-by-claim basis, giving litigation teams a data-driven picture of their exposure before a single deposition is scheduled.
As of June 9, 2026, the legal software market for IP-focused applications is expanding rapidly, with adoption of AI contract review platforms and patent analysis tools accelerating across both plaintiff and defense practices, according to legal industry survey data. Legal technology has also compressed the timeline for prior-art searches — a critical step in patent litigation where defendants attempt to invalidate the plaintiff's patent by proving the invention was already publicly known before the filing date. The medical AI sector is learning, case by contested case, that the same technological wave producing breakthroughs in patient care is simultaneously arming the attorneys fighting over ownership of those breakthroughs.
What Should You Do? 3 Action Steps
Before deploying any third-party AI-driven medical platform, request a written IP representation from the vendor confirming that their technology does not infringe known third-party patents. Ask specifically whether the product has been reviewed by patent counsel, and verify that your licensing agreement includes indemnification language — a contractual promise that the vendor will defend you if a rights-holder comes after your organization. A focused contract review of vendor agreements is the first defensive step — and AI legal tools can dramatically accelerate this audit across a large portfolio of existing vendor contracts, flagging missing or narrow indemnification provisions at scale.
Many healthcare organizations assume that legitimately licensing a product fully insulates them from downstream IP liability. Under direct infringement doctrine, that assumption is legally incorrect. Review every active vendor agreement for patent indemnification provisions — language that requires the supplier to defend you and cover costs if a third party claims the licensed tool infringes their patent. Legal software platforms designed for contract review can flag these gaps in minutes across dozens of agreements. If the language is absent or narrowly drafted, an IP attorney can help negotiate stronger protective terms before a dispute arises rather than after a complaint is filed.
For companies developing proprietary AI-driven healthcare tools, the time to protect intellectual property is before the product reaches market — not after a competitor has already incorporated your approach. Patent applications must be drafted with claims that describe the specific technical implementation of your algorithm: the precise architecture, training procedure, and data pipeline, not the general concept of applying machine learning to a clinical problem. Law firm automation and legal technology have made the IP prosecution process more efficient, but there is no substitute for a registered patent attorney who understands both the clinical application domain and the underlying software architecture. As of June 9, 2026, the U.S. Patent and Trademark Office reports average utility patent pendency of approximately 23 to 24 months — meaning a filing made today protects your competitive position in tomorrow's market.
Frequently Asked Questions
Can an AI algorithm embedded in a medical device actually be protected by a U.S. patent?
Yes, under the right conditions. U.S. patent law protects AI algorithms when they are claimed as part of a specific, novel technical process or system — not as an abstract idea in isolation. The governing test comes from the Supreme Court's Alice Corp. v. CLS Bank (2014) decision: the patent must describe an inventive concept that goes meaningfully beyond applying a general computational method. Medical AI patents describing specific architectures, custom training procedures, or clinical decision workflows tied to a concrete technical improvement are substantially more durable against validity challenges than broad, concept-level claims. The "piracy" framing in the June 9, 2026 lawsuit reported by The National Law Review suggests the plaintiff believes its patents clear this bar.
What does "patent infringement" actually mean in plain English for a hospital using AI diagnostic tools?
It means using, selling, or incorporating a patented invention without the owner's permission. For hospitals and health systems, the practical risk is this: if an AI diagnostic platform you licensed from a vendor turns out to incorporate methods patented by someone else — without authorization — your organization could be named in a lawsuit as an end user who "used" the infringing invention. The direct infringement standard under 35 U.S.C. § 271 does not require that you knew the technology was disputed. This is why legal software-assisted reviews of vendor agreements have become standard risk-management practice in healthcare technology procurement.
How does a court actually determine whether two AI medical systems are close enough to constitute patent infringement?
Courts conduct a detailed "claim construction" analysis, interpreting exactly what each patent claim covers in technical terms, then comparing those construed claims to the accused product's actual implementation. For AI systems, this typically involves expert testimony from engineers or clinical informaticists who examine the model architecture, training methodology, data preprocessing pipeline, and inference logic to determine whether the accused product practices the specific steps described in the patent. Surface-level similarity between two AI diagnostic tools is insufficient — the comparison must map to the specific language of the patent claims.
What immediate steps should a medical AI startup take right now to protect its intellectual property from being copied?
Three priorities: First, file a provisional patent application as soon as your core technical approach is defined — this establishes a priority date without requiring a completed application and costs significantly less than a full filing. Second, document your development process rigorously through version-controlled code, dated design records, and internal memos, which establish independent creation if your priority date is ever disputed in litigation. Third, conduct a "freedom to operate" analysis before launch, using legal technology and AI patent search tools to confirm your product does not inadvertently infringe existing patents. Law firm automation tools can assist with the search, but a registered patent attorney with medical device or software experience remains essential for interpreting results and drafting defensible claims.
Can a healthcare company be held liable for patent infringement if the AI software vendor was the one that actually copied the technology?
Potentially yes. Under 35 U.S.C. § 271(a), any entity that "uses" a patented invention without authorization — including good-faith end users — can face direct infringement liability. The primary safeguard is a robust indemnification clause in the vendor contract, which shifts the defense obligation and financial exposure back to the supplier who provided the infringing tool. Healthcare organizations should treat AI tool vendor agreements with the same scrutiny applied to any major legal software or infrastructure contract. Without proper indemnification language, an organization that unknowingly licensed a "pirated" AI medical platform could find itself co-defending a lawsuit — and absorbing legal costs — alongside the vendor that copied it.
Explore Our Network
